As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
June 7, 2019
| By Fred Hutch News Service staff
A new study led by physicians at Fred Hutchinson Cancer Research Center shows that patients with HIV and one of a variety of potentially deadly cancers can be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
June 4, 2018
| by Susan Keown / Fred Hutch News Service
Immunotherapy drugs have transformed the treatment of a deadly skin cancer, Merkel cell carcinoma. New trial results show these drugs help many patients survive much longer than would otherwise be possible.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.